| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 45.0 | 13.1 |
| Profit before tax | -41.9 | -55.8 |
| Net income | -41.9 | -55.8 |
| EPS (diluted, $ a share) | $-0.12 | $-0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +242.6% |
|---|---|
| Operating margin | -93.9% |
10-Q filed with the SEC, NYSE: NUVB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nuvation Bio Inc.: key numbers
- Share price
- $3.84Close, Nov 16
- Market cap
- $1.36B
- Shares outstanding
- 353.02MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nuvation Bio Inc.
All →Nuvation Bio Earnings Call: Key Takeaways
Nuvation Bio reported strong Iptrosi growth despite a 15% market-wide decline in ROS1 TKI starts, while advancing its IDH1 mutant glioma program toward 2027 data readouts.
- Call
- Nov 4, 2026, 4:30 PM ET
Nuvation Bio Financial Results
Nuvation Bio reported third quarter 2026 financial results, highlighted by $45.0 million in total revenue and $27.5 million in net product revenue for its ROS1 inhibitor IBTROZI. The company ended the quarter with $663.4 million in cash and marketable securities while achieving market leadership in new patient starts for ROS1+ NSCLC.
“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data.”
David Hung, M.D., Founder, President, and Chief Executive Officer
“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI’s durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy.”
David Hung, M.D., Founder, President, and Chief Executive Officer